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Increasing evidence suggests that kynurenine pathway (KP) dyshomeostasis may promote disease progression in de
mentia. Studies in Alzheimer's disease (AD) patients confirm KP dyshomeostasis in plasma and cerebrospinal fluid (CSF)
which correlates with amyloid-β and tau pathology. Herein, we performed the first comprehensive study assessing
baseline levels of KP metabolites in participants enrolling in the Australian Imaging Biomarkers Flagship Study of Aging.
Our purpose was to test the hypothesis that changes in KP metabolites may be biomarkers of dementia processes that are
largely silent. We used a cross-sectional analytical approach to assess non-progressors (N = 73); cognitively normal (CN)
or mild cognitive impairment (MCI) participants at baseline and throughout the study, and progressors (N = 166); CN or
MCI at baseline but progressing to either MCI or AD during the study. Significant KP changes in progressors included
increased 3-hydroxyanthranilic acid (3-HAA) and 3-hydroxyanthranilic acid/anthranilic acid (3-HAA/AA) ratio, the
latter having the largest effect on the odds of an individual being a progressor (OR 35.3; 95% CI between 14 and 104). 3HAA levels were hence surprisingly bi-phasic, high in progressors but low in non-progressors or participants who had
already transitioned to MCI or dementia. This is a new, unexpected and interesting result, as most studies of the KP in
neurodegenerative disease show reduced 3-HAA/AA ratio after diagnosis. The neuroprotective metabolite picolinic acid
was also significantly decreased while the neurotoxic metabolite 3-hydroxykynurenine increased in progressors. These
results were significant even after adjustment for confounders. Considering the magnitude of the OR to predict change in
cognition, it is important that these findings are replicated in other populations. Independent validation of our findings
may confirm the utility of 3-HAA/AA ratio to predict change in cognition leading to dementia in clinical settings.

Abbreviations: AA, anthranilic acid; Aβ, amyloid beta; Aβ42, 42-residue form of amyloid beta; AIBL, Australian Imaging, Biomarkers and Lifestyle flagship study of
aging; 3-HAA, 3-hydroxyanthranilic acid; 3-HK, 3-hydroxykynurenine; KMO, kynurenine 3-monooxygenase; KP, kynurenine pathway; KYN, kynurenine; KYNA,
kynurenic acid; NAD+, nicotinamide adenine dinucleotide; NMDA, N-methyl D-aspartate; PARP, poly ADP-ribose polymerase; p-tau, hyperphosphorylated tau; QUIN,
quinolinic acid; TRP, tryptophan; t-tau, total tau; XA, xanthurenic acid.
* Corresponding authors.
E-mail addresses: james.doecke@csiro.au (J.D. Doecke), gilles.guillemin@mq.edu.au (G.J. Guillemin), david.lovejoy@mq.edu.au (D.B. Lovejoy).
1
These authors contributed equally.
https://doi.org/10.1016/j.nbd.2022.105783
Received 24 October 2021; Received in revised form 30 May 2022; Accepted 1 June 2022
Available online 5 June 2022
0969-9961/© 2022 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

M. Cespedes et al.

Neurobiology of Disease 171 (2022) 105783

2019). Other KP metabolites coordinate aspects of the immune response.
Levels of 3-HK and 3-hydroxyanthranilic acid (3-HAA) modulate T-cell
activity in the immune system, with higher 3-HAA concentrations
reducing cytokine release from T-helper (Th) cells (Hayashi et al., 2007).
How KP dysregulation meshes with the overall clinical picture of
dementia, including AD, is emerging. Activated microglia and reactive
astrocytes are known to surround amyloid plaques and intracellular
neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau (ptau) (Osborn et al., 2016; Masters et al., 2015). At least initially, these
glial cells exert a repair by clearance function, but chronic induction of
activated microglia produces pro-inflammatory cytokines linked to
neuroinflammation which is then linked to the progression of dementia
at both pathological and clinical levels (Masters et al., 2015; Heneka
et al., 2015). Simultaneously, chronically activated microglia produce
excess QUIN (Guillemin, 2012). These overlapping events may account
for the clinical observations in AD patient post-mortem hippocampal
tissue that show correlations between QUIN concentrations and the
presence of amyloid (Guillemin et al., 2005) and tau (Wu et al., 2013),
particularly when it is further appreciated that in vitro studies show that
QUIN promotes hyper-phosphorylation of tau protein (Rahman et al.,
2009).
Clinical evidence further confirms significant changes in KP metab
olite concentrations and KP enzyme activity in the sera/plasma/CSF of
AD patients compared to normal controls (Gulaj et al., 2010; Schwarz
et al., 2013; Giil et al., 2017; Jacobs et al., 2019). In the Gulaj study,
serum QUIN concentrations were 1.7-fold higher in AD patients
compared to controls while the QUIN/3-HK ratio, increased 2-fold. In
histopathologically confirmed AD patients, plasma TRP, 3-HAA, xan
thurenic acid (XA) and QUIN were significantly decreased compared to
cognitively normal controls (Odds ratios; 0.24–0.47; p-values
<0.001–0.01) (Giil et al., 2017). As samples from histopathologically
confirmed patients represent very late-stage disease, this observation of
decreased QUIN agrees with findings of other studies showing that QUIN
concentrations peak at mid-stages of AD before decreasing in late-stage
disease (Guillemin et al., 2005). Interestingly, these authors also re
ported that increased QUIN correlated with reduced cognitive perfor
mance in elderly AD patients (Giil et al., 2017), where patients are less
advanced and QUIN levels are higher. Significant positive associations
between plasma Aβ42 and the KP metabolites, kynurenine (KYN; r =
0.467, p = 0.007), KYNA (r = 0.214, p = 0.035), anthranilic acid (AA; r
= 0.576, p = 0.0006), QUIN (r = 0.539, p = 0.001) and the kynurenine
to tryptophan (K/T) ratio (r = 0.494, p = 0.004) were also reported in
individuals with high neocortical Aβ load, whereas these associations
were absent in participants with low Aβ load (Chatterjee et al., 2019).
More recently, we demonstrated that in AD patients, plasma KYN
and picolinic acid (PIC) were inversely correlated with CSF p-tau and
total tau (t-tau), respectively. Increased 3-HK/KYN ratio also correlated
with increasing t-tau and p-tau (Jacobs et al., 2019). Another study also
reported KP correlations with increased KYNA and QUIN in the CSF of
AD patients correlating with amyloid β1–42, tau and/or phosphorylated
tau-181 (van der Velpen et al., 2019). Although clinical studies of the KP
in neurodegenerative disease differ in design and often yield different
results, there is general consensus that KP activation occurs in AD pa
tients (as reflected by increased K/T ratio) with most studies also
showing increased concentrations of the highly neurotoxic metabolites
QUIN and 3-HK.
Considering the spectrum of clinical evidence, therapeutic modula
tion of the KP, aimed at rebalancing the ratio of neuroprotective/
neurotoxic KP metabolites by inhibiting KP enzymes, has attracted sig
nificant research effort. Most focus has centered on the KP enzyme
kynurenine 3-monooxygenase (KMO) following the demonstration that
KMO inhibition improved various indicators of disease progression in
murine models of AD and Huntington's disease (Zwilling et al., 2011).
Despite considerable interest in the KP in AD and neurodegenerative
disease, most reports are single-point studies assessing KP metabolites
after disease diagnosis. No studies have yet assessed KP metabolites in

1. Introduction
Chronic neuroinflammation plays a known role in the progression of
dementia and Alzheimer's disease (AD) by increasing amyloid (Minter
et al., 2016) and tau (Didonna, 2020) toxicity. The kynurenine pathway
(KP, Fig. 1) of tryptophan (TRP) metabolism is also dysregulated by
chronic inflammation, which in-turn, may feedback to enhance
dementia-related neuroinflammatory processes. Mechanistically,
neuroinflammation-driven changes in the KP lead to excessive produc
tion of the KP metabolite quinolinic acid (QUIN) which causes excito
toxic overstimulation of the N-methyl D-aspartate (NMDA) receptor,
inducing a cascade of molecular events that lead to neuronal death
(Jacobs et al., 2017).
In addition to NMDA receptor-mediated excitotoxicity, QUIN medi
ates neurotoxicity by multiple other mechanisms, including the forma
tion of redox-active metal complexes, poly ADP-ribose polymerase
(PARP) activation and nicotinamide adenine dinucleotide (NAD+)
depletion (Braidy et al., 2009). Importantly, in both neurons and as
trocytes, QUIN at very low concentrations (<50 nM), leads to the
cellular energy factor nicotinamide adenine dinucleotide (NAD+) which
is essential for maintaining brain energy homeostasis and healthy brain
aging. However, QUIN is cytotoxic at sub-physiological concentrations
(>150 nM) in both the cell types (Braidy et al., 2009). The KP metabolite
kynurenic acid (KYNA) produced by astrocytes acts as an endogenously
produced neuroprotective molecule able to antagonize QUIN excito
toxity at the NDMA receptor (Jacobs et al., 2017). Also implicated in
neurotoxicity is the KP metabolite 3-hydroxykynurenine (3− HK) which
was recently shown to induce mitochondrial membrane destabilization
and disrupt the oxygen respiratory chain (Castellano-Gonzalez et al.,
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Fig. 1. Simplified schematic of the kynurenine pathway (KP). Key aspects of
the KP include: Induction of the KP enzymes indolamine 2,3 deoxygenase (IDO1 and IDO-2) or tryptophan 2,3 deogygenase (TDO-1 and TDO-2) results in the
conversion of tryptophan (TRP) to kynurenine (KYN). The enzyme kynurenine
3-monooxygenase (KMO) is located at a key branch point of the KP. The activity
of KMO determines if KYN is metabolised to the redox active and immuno
modulatory metabolites 3-hydroxykynurenine (3-HK) and 3-hydroxyanthranilic
acid (3-HAA) which in turn leads to production of the neurotoxic metabolite
quinolinic acid (QUIN) or by kynurenine aminotransferase (KAT) to the neu
roprotective metabolite kynurenic acid (KYNA). Activity of the enzyme qui
nolinate phosphoribosyl transferase (QPRT) ultimately leads to the essential
cellular energy factor nicotinamide adenine dinucleotide (NAD+). Highlighted
in blue are KP metabolites measured within this study, while red text indicates a
KP enzyme.
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otherwise healthy participants and followed clinical course. Hence, our
purpose was to address this gap, by conducting a study using samples
from the Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship
study of aging. Initially, we used a cross-sectional analytical design to
test the hypothesis that baseline levels of metabolites in the KP would be
associated with clinical disease progression, defined as a change in
classification from cognitively normal (CN) to mild cognitive impair
ment (MCI) or from MCI to AD, henceforth denoted as progressors. The
design also assessed longitudinal data in terms of how KP modulations in
progressors may be related to changes in clinical classification.

this work is the comparison of metabolites in the KP between pro
gressors and non-progressors, only general summaries of the 47 in
dividuals who commenced the study with AD are provided. Plasma KP
data obtained from baseline samples were analyzed with respect to
change in clinical classification between 2008 and 2020. The results
presented here in the Tables and Figures denote non-progressors and
progressors by clinical classification at baseline as either CN or MCI,
prior to any cognitive change.

2. Methodology

2.3.1. Plasma preparation
Briefly, all blinded plasma samples were deproteinized with equal
volumes of 10% w/v trichloroacetic acid (TCA) followed by centrifu
gation (3600 g at 4 ◦ C for 15 min). Supernatants were harvested, filtered
through 0.45 μm polytetrafluoroethylene syringe filters (Merck-Milli
pore, CA, USA) and stored at − 80 ◦ C prior to analysis.

2.3. Kynurenine metabolite analysis by UHPLC, HPLC and GC/MS

2.1. Participants
Initiated in 2006, AIBL is Australia's largest study of aging, aimed at
understanding which blood, imaging, genetic, demographic, modifiable
risk factors, and/or cognitive markers influence the development of AD.
Participants were followed-up at approximately 18-month intervals, for
up to 12 years (144 months). A subset of 286 AIBL participants (152 CN, 87
MCI and 47 AD at baseline) was selected at random for the conduct of a
pilot study investigating baseline plasma levels of metabolites in the KP
across the pre- and post- dementia diagnosis spectrum. Demographic and
clinical information including age, sex, apolipoprotein E (APOE) ε4 allele
status (major genetic risk factor for AD), the Mini-Mental State Exam
(MMSE) score, Clinical Dementia Rating (CDR) global score and the AIBL
preclinical Alzheimer's cognitive composite score (AIBL PACC) derived by
(Donohue et al., 2014) were used to investigate the relationship of KP
metabolites to cognition (Table 1). Further details of the AIBL study
protocol and methods can be found elsewhere (Fowler et al., 2021).

2.3.2. Quantification of KP metabolites
TRP, KYN, 3-HK, 3-HAA and AA were quantified by ultra-highperformance liquid chromatography (UHPLC) in accordance with pub
lished methods (Guillemin et al., 2007). KYNA analysis was performed
by high performance liquid chromatography (HPLC) using an Agilent
1260 system with fluorescence detection (ex: 344 nm and em: 388 nm)
in accordance with published methods (Lim et al., 2017). PIC and QUIN
metabolites were quantified using gas chromatography (GC; Agilent
5975 system) coupled with mass spectrometry (MS; Agilent 7890 sys
tem) as adapted from published methods (Lim et al., 2017).
2.4. Positron emission tomography (PET) imaging
PET Aβ neuroimaging was conducted using either 11C-Pittsburgh
compound-B (PiB), 18F-Florbetapir (FBP), or 18F-Flutemetamol
(FLUTE) tracers with brain Aβ represented as centiloid (CL) values.
Detailed information regarding the PET procedures, including deriva
tion of PET Aβ status has been reported previously (Bourgeat et al.,
2018; Rowe et al., 2010). Of the total 286 participants, only 113 had PET
imaging data available (Aβ-: N = 51, Aβ+: N = 61). Complete sample
size breakdown between clinical classification, progressor groups and
Aβ groups is shown in Supplementary Table 1.

2.2. Sample selection for progressor and non-progressor groups
Participant selection from the overall AIBL population through to
those individuals included in the current analyses is shown in Fig. 2.
From the subset of 286 randomly selected AIBL participants, 166 pro
gressed from either CN at baseline to MCI (N = 101) or from MCI at
baseline to AD (N = 65), denoted as progressors; while only 73 partic
ipants (51 CN and 22 MCI), denoted as non-progressors, remained at
their baseline clinical state at all subsequent follow-ups. As the focus of
Table 1
Cohort demographics.
Non-progressor (NP)

N (%)
Gender Male, N (%)
Mean Age, years (SD)
APOE ε4 Carrier, N (%)

All

CN

MCI

73
35 (48)

51 (70)
23 (45)
75.5
(5.3)
11 (22)

22 (30)
12 (55)

Mean Centiloid (SD)*
PET-Aβ + ve, N (%)*

75.7 (5.8)
24 (33)
28.7
(43.2)
13 (25)

Mean MMSE (SD)
Mean CDR global (SD)

28.3 (1.6)
0.2 (0.2)

1.3 (4.3)
9 (21)
28.9
(1.1)
0 (0.1)

Mean AIBL PACC (SD)
Mean months follow-up
(SD)

0.4 (1)

0.1 (0.5)

CN vs
MCI
p-value

AD at
baseline

Progressor (P)
All

CN

MCI

NP vs P
CN
p-value

NP vs P
MCI
p-value

0.8466

0.6479

0.7573

CN vs
MCI
p-value

0.6269

47 (39)
21 (45)

166
82 (49)

101 (61)
51 (50)

65 (39)
31 (48)

74.9 (7.2)
88 (53)
59.4
(46.9)
42 (75)

73.7 (7)
45 (45)
40.6
(42.6)
24 (63)

76.7 (7.2)
43 (66)
80.5
(42.8)
18 (100)

0.0084
0.0104

0.0701
0.0094

0.7778
0.7336

0.0002
0.0022

<0.0001
0.0002

0.3761
0.023

27.4 (2.3)
0.2 (0.3)
− 1.3
(1.1)

28.4 (1.3)
0.1 (0.2)
− 0.6
(0.6)
73.4
(26.2)

25.7 (2.6)
0.5 (0)
− 2.3
(0.7)
65.9
(22.6)

<0.0001
<0.0001

0.0136
0.0603

0.0171
0.1621

<0.0001

<0.0001

0.0078

76.2 (7)
13 (59)
69
(42.9)
4 (57)

0.6795
0.0042

77.7 (7.1)
33 (70)

<0.0001
0.0605

112.8 (35.1)
6 (100)

27 (1.9)
0.5 (0.1)

0.0001
<0.0001

14.6 (7.8)
1.8 (0.8)

− 1.6 (1)

<0.0001

− 3.9 (1)

70.5 (25)

0.0511

Baseline demographic summaries for clinical diagnosis categories for non-progressors and progressor participants. N denotes the number of participants, with per
centage (%) or standard deviation (SD) in parenthesis. Cognitively normal (CN); mild cognitive impaired (MCI); Alzheimer's disease (AD); Apolipoprotein E ε4 allele
carriers (APOE ε4); Positron Emission Topography (PET) amyloid burden was measured by the centiloid value; Mini-Mental State Exam (MMSE); Clinical Dementia
Rating (CDR); Australian Imaging, Biomarkers and Lifestyle Preclinical Alzheimer's Cognitive Composite (AIBL PACC). * denotes a reduced sample size of N = 112. Pvalue represents the comparison between non-progressor and progressor (All) groups. Comparisons between CN non-progressors and CN progressors MCI nonprogressors and MCI progressors are not shown Comparison between CN and MCI progressor mean months follow-up is 0.0511.
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Fig. 2. Derivation of Australian Imaging,
Biomarkers and Lifestyle (AIBL) partici
pant sample size used in the current study.
NTOTAL denotes the total AIBL study sam
ple size, N denotes the number of partici
pants at each step. This study focuses on
the analyses of longitudinal clinical clas
sification (defined as progressors and nonprogressors) with respect to participants
baseline Kynurenine Pathway (KP)
metabolite information. CN: cognitively
normal, MCI: mild cognitive impairment
and AD: Alzheimer's disease.

AIBL study NTOTAL = 2239
Fowler et. al 2021

Participants with baseline and/ or longitudinal KP
metabolite and clinical classification data
N = 308

Outliers removed
Outliers were found on follow-up KP metabolite data
N = 308

Participants with at least one or more follow-up in
clinical diagnosis
N = 286

Progressors
Baseline CN/ MCI and
deteriorated to
MCI/AD at a later
follow-up
N = 166

Baseline AD
Individuals who
commenced the study
with clinical AD
diagnosis
N = 47

Non-progressors
Baseline CN/ MCI
individuals who
remained CN/MCI for
all follow-ups
N = 73

N = 166

N=1

N=0

2.5. Statistical analysis

only (Table 1). Remaining characteristics such as APOE ε4 carrier fre
quency, mean CL, MMSE, CDR global and AIBL PACC score were all
significantly different between clinical classifications within both pro
gressor and non-progressor groups (p < 0.05) as shown in Table 1.
Participants who were CN at baseline and did not progress over the
length of the study were less likely to have an APOE ε4 allele as
compared to those CN participants who did progress (CN non-progressor
22% vs CN progressor 45%, p = 0.0094). For participants classified as
MCI at baseline, APOE ε4 allele status was not significantly different
between progressor and non-progressor groups (MCI non-progressor
59% vs MCI progressor 66%, p = 0.73). Baseline age was not signifi
cantly different between participants who were either CN or MCI in the
non-progressor group (p = 0.6795), however MCI participants in the
progressor group were significantly older than their CN counterparts (p
= 0.0084) as show in Table 1.
Of the total sample size (N = 286) 65 participants who were MCI at
baseline and progressed to AD during the study were no more likely to be
Aβ + as compared to the 22 participants who were MCI and did not
progress (p = 0.73); however, this result should be interpreted with
caution due to the small sample size meeting these clinical classification
criteria coupled with available PET data.

Demographic characteristics for baseline clinical classifications were
compared within each progressor/non-progressor group using Chisquared (gender) and Fisher (APOE ε4 allele status) tests. Investiga
tion of metabolite levels between both progressor/non-progressor
groups, and CN/MCI across progressor/non-progressor groups was
performed using standard comparison of marginal means. Adjustment
for confounders was performed using Generalised Linear Modelling,
with conversion of beta coefficients to odds ratios to assess risk levels.
Further details on data handling and statistical analyses can be found in
the Supplementary materials section.
3. Results
3.1. Sample demographics
Comparison of demographic and clinical characteristics within both
progressor and non-progressor groups showed no difference in the fre
quencies of males to females (p > 0.05), whilst participants with MCI
were significantly older than CN participants in the progressor group
4
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Within the progressor group, the mean number of months of cogni
tive follow-up time was slightly less for participants who were MCI at
baseline (65.9 months) as compared with those participants who were
CN at baseline (73.4 months), even though this difference did not quite
reach statistical significance (p = 0.0511). Correlation plots of
biomarker trajectories with age, for all available samples are shown in
Supplementary Figs. 1 and 2.

(in either or both Aβ− /Aβ + groups), excluding AA, were seen between
non-progressor and progressor groups, however only at the nominal
significance level (p < 0.05, Supplementary Table 2, Supplementary
Figs. 4 & 5).

3.2. Metabolite biomarker mean comparisons across progressor groups
Four- and three-fold higher unadjusted baseline means for 3-HAA
and 3-HAA/AA ratio respectively, were observed for progressors
compared to non-progressors (p-values <0.0001 across all baseline
groups), as shown in Table 2 and Fig. 3. To a lesser extent, 3-HK and the
3-HK/KYN ratio values were also higher in progressor participants (3HK/KYN ratio: 54.71 compared to 48.25; p-value 0.0001). Compared
with non-progressors, baseline mean PIC and QUIN/KYNA ratio levels
were 27.4% and 26.9% lower, respectively, for progressor participants
(p-values <0.0064 for both metabolites). Cognitively normal nonprogressors showed lower baseline concentrations of TRP, 3-HK and
KYNA metabolites compared to progressor groups (all p-values <0.014)
but showed higher QUIN, K/T and PIC/QUIN ratios than progressor
groups (p-values <0.0351). Refer to Table 2 and Supplementary Fig. 3
for all numeric and visual comparisons of baseline mean KP metabolites.

The effect of a metabolite biomarker on the odds of a participant
being a progressor compared to a non-progressor is shown in Table 3,
after adjusting for confounders (age, gender and APOE ε4 allele status).
The 3-HAA/AA ratio was found to have the largest effect on the odds of
an individual being a progressor (OR 35.3; 95% CI between 14 and 104).
This OR suggests that a one unit increase in 3-HAA/AA for a CN/MCI
participant (for example, moving from 0.33 to 1.33) equates to a
participant being approximately 35 times more likely to progress to
either MCI or AD. Similarly, but to a lesser extent, other metabolites in
the KP which were found to significantly increase the odds of an indi
vidual being a progressor were 3-HAA (OR 1.19; 95% CI between 1.01
and 1.25) and 3-HK/ KYN ratio (OR 1.04; 95% CI between 1.02 and
1.07). In the opposite direction, where a lower metabolite biomarker
level equates to lower odds of an individual being a progressor, are
QUIN/KYNA, PIC and PIC/QUIN ratios, with OR of magnitudes 0.99,
0.981 and 0.0013 respectively (all with p-values <0.01).

3.3. Metabolite biomarker mean comparisons across PET Aβ groups

3.5. Changes in metabolite levels with age

Assessing differences in KP metabolites between PET Aβ groups,
there were nominally significant changes in TRP, AA, KYN, QUIN and
3HK metabolites (Supplementary Table 2), although these did not meet
the adjusted significance level. Both 3-HAA and its ratio with AA were
significantly higher in progressors as compared with non-progressors in
both Aβ- and Aβ + groups (P < 0.0001). Changes in all other metabolites

Combining all participant data, we assessed metabolite biomarkers
with respect to age, irrespective of clinical classification, to ensure either
an increase or decrease with age occurred as expected. No interactions
were found between metabolite biomarkers and clinical classification
with age (data not shown) given that both CN and MCI groups contain
both progressors and non-progressors. There was a large separation in

3.4. Metabolite biomarker effect size on the odds of a progressor
individual

Table 2
Metabolite mean comparisons.
Metabolite

Non-progressor
Non-progressor (N
= 73)

CN (N =
51)

TRP
KYN

42.78 (7.61)
2.21 (0.46)

3-HK

104.93 (19.62)

42.2 (6.71)
2.21 (0.44)
104.66
(16.57)

3-HAA

6.48 (7.81)

AA

24.3 (8.5)

PIC

306.21 (93.36)

QUIN

1475.7 (425.9)

KYNA

20.24 (7.36)

K/ T

52.22 (13.16)

3-HK/ KYN
3-HAA/ AA
PIC/ QUIN
QUIN/
KYNA

48.25 (9.98)
0.3 (0.37)
0.22 (0.09)
85.59 (37.12)

5.26 (4.75)
23.99
(8.43)
296.14
(84.41)
1452.4
(425.8)
20.13
(6.94)
53.59 (13)
47.73
(9.43)
0.25 (0.28)
0.22 (0.08)
83.76
(36.61)

MCI (N =
22)
44.14
(9.42)
2.19 (0.5)
105.56
(25.79)
9.33
(11.97)
25.02 (8.8)
329.55
(110.0)
1529.6
(431.3)
20.51
(8.41)
49.04
(13.29)
49.45
(11.28)
0.41 (0.52)
0.22 (0.09)
89.81
(38.81)

AD at baseline (N
= 47)

Progressor
Progressor (N =
166)

38.4 (6.94)
2.15 (0.64)

44.81 (6.89)
2.14 (0.43)

101.92 (19.48)

115.17 (29.44)

9.4 (8)

27.49 (14.57)

27.71 (11.73)

26.8 (10.82)

284.11 (113.2)

222.31 (88.18)

1429.5 (565.2)

1303.6 (480.1)

17.85 (7.6)

22.83 (7.98)

54.35 (13.2)

48.95 (12.01)

49.66 (13.61)
0.38 (0.37)
0.21 (0.09)

54.71 (14.84)
1.14 (0.7)
0.18 (0.08)

81.24 (32.19)

62.58 (30.64)

Unadjusted p-values

CN (N =
101)

MCI (N =
65)

45.28
(6.83)
2.1 (0.4)
114.91
(29.5)
26.77
(14.91)
25.89
(11.31)
226.89
(97.51)
1274.6
(468.4)
23.36
(8.61)
47.17
(10.19)
55.33
(14.65)
1.15 (0.7)
0.19 (0.08)
62.1
(31.76)

44.08
(6.96)
2.21 (0.47)
115.58
(29.58)
28.6
(14.07)
28.2 (9.95)
215.19
(71.46)
1348.8
(498.1)
22 (6.85)
51.72
(14.03)
53.74
(15.19)
1.13 (0.69)
0.17 (0.07)
63.34
(29.02)

All

CN

MCI

0.0533
0.3244

0.0092
0.1233

0.9813
0.8387

0.0018

0.0069

0.1371

<0.0001

<0.0001

<0.0001

0.0573

0.2493

0.1653

<0.0001

<0.0001

0.0001

0.0064

0.0205

0.1103

0.0159

0.014

0.4571

0.0718

0.0028

0.4254

0.00011
<0.0001
0.0018

0.00016
<0.0001
0.0351

0.167
<0.0001
0.0313

<0.0001

0.0005

0.0064

Baseline mean metabolite comparisons for non-progressor and progressor participants across clinical classification groups; cognitively normal (CN), mild cognitive
impaired (MCI) and Alzheimer's disease (AD) participants. Mean metabolite values and standard deviations in parenthesis. TRP (Tryptophan), KYN (kynurenine), 3-HK
(3-hydroxykynurenine), 3-HAA (3-hydroxyanthranilic acid), AA (anthranilic acid), PIC (picolinic acid), QUIN (quinolinic acid), KYNA (kynurenic acid), and K/T
(kynurenine/ tryptophan ratio). Pairwise comparisons were assessed across all clinical classification groups within non-progressor and progressor participants; refer to
Fig. 2 for significant comparisons. P-value All refers to the unadjusted comparison between non-progressor (N = 73) and progressor (N = 166) groups, P-value CN
refers to the unadjusted comparison between non-progressor CN (N = 51) and progressor CN (N = 101) groups, P-value MCI refers to the unadjusted comparison
between non-progressor MCI (N = 22) and progressor MCI (N = 65) groups.
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Fig. 3. Baseline metabolite value comparisons across Progressor and clinical classification groups.
Baseline mean metabolite values for progressors, non-progressors, and Alzheimer's disease (AD) at baseline. 3-HAA (3-hydroxyanthranilic acid), PIC (picolinic acid),
3-HAA/ AA (anthranilic acid) ratio, QUIN/ KYNA (quinolinic acid/ kynurenic acid) ratio, and 3-HK/ KYN (3-hydroxykynurenine/ kynurenine) ratio. Colour coded
into clinical classification; cognitively normal (CN, green), mild cognitive impaired (MCI, yellow) and Alzheimer's disease (AD, red). Statistical significance denoted
by * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001.

values between progressors and non-progressors for 3-HAA and the 3HAA/AA ratio, however, slopes were similar amongst all groups (Sup
plementary Figs. 1 and 2). Spearman's correlation between each
metabolite and age showed moderate but significant associations, with
KYN, PIC, AA, QUIN the K/T ratio and the QUIN/KYNA ratio increasing
with age, and TRP, 3-HK/KYN and PIC/QUIN decreasing with age.

4. Discussion
This is the first study that investigated whether baseline levels of KP
metabolites were different in participants who underwent a subsequent
change in their clinical disease stage during their time in the AIBL study
compared to matched individuals whose disease stage remained stable.
While large changes in 3-HAA occurred in progressors, this was not
specific to the presence of significant amyloid pathology, as similar
changes were seen in progressors whose amyloid levels remained within
normal limits. It had been previously reported that higher levels of the
KP metabolites KYNA, QUIN and PIC and a higher K/T ratio after AD
diagnosis were associated with increased cognitive decline in patients
without the APOE ε4 allele but not in those with APOE ε4 (Ervik et al.,
2019). Another earlier single-point post-diagnosis study showed
decreased KYNA, but stable KYN levels, in plasma and red blood cells in
both APOE ε4 and non-APOE ε4 AD patients, which is in agreement with
the current study (Hartai et al., 2007).
The lack of direct correlation of plasma KP parameters to Aβ load

3.6. Changes in metabolite levels by gender
Given that the metabolome has been shown to vary by gender in
MCI/AD, we also assessed the influence of gender on KP metabolites in
the AIBL cohort. This analysis showed that there are no significant dif
ferences by gender in all the KP metabolites (Supplementary Figs. 6 and
7). While there are some gender differences in 3HAA and 3HAA/AA
ratio, these are only apparent in participants >87 yrs. of age and are
likely skewed due to the small numbers of participants aged >87 yrs.
(male n = 6; female n = 13).
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is interesting to note that the current study also found that 3-HAA was
decreased in symptomatic AD study participants relative to progressors.
Further evidence of the interplay between 3-HAA levels, inflammation
and cognition recently emerged in a study of participants with pre- and
type 2 diabetes (Bakker et al., 2021). 3-HAA was associated with lower
odds of cognitive decline in both groups (OR per SD 0.67 [96% CI 0.47,
0.96] in prediabetes and 0.73 [0.60, 0.87] in type 2 diabetes). It is
important to note that decreased 3-HAA, rather than decreased AA,
accounts for the increased plasma 3-HAA/AA ratio in progressors.
Why the plasma 3-HAA/AA ratio reverses and increases prior to
progression to MCI or AD, before returning to the same level as CN nonprogressors or symptomatic AD participants, is an interesting question.
One possibility is that AD medications might interact directly or indi
rectly with the KP. However, no direct effects of galantamine, donepezil
or other acetylcholinesterase (AChE) inhibitors on 3-HAA or AA have
been reported to date, although one study showed approximately 20%
reductions in KYNA and PIC in a limited number of patients (Koola et al.,
2018). Also arguing against a potential drug effect is that AD medica
tions tend to be taken for a relatively short period as effectiveness is
limited and decreases over time. A variety of dietary supplements are
also commonly used in dementia with no studies assessing the effects of
ginkgo biloba, coconut oil or vitamin D supplementation on the KP. There
is some evidence that a ginseng extract (Kang et al., 2017), resveratrol
(Wirleitner et al., 2005) or curcumin (Zhang et al., 2019) can favorably
remodulate the KP, although further studies are needed to confirm ef
fects on the KP. Hence, it is possible that use of these supplements by
study participants may have affected results. An alternate explanation
may be that prodromal disease phase processes drive molecular changes
that skew the KP, leading to increased 3-HAA, but which diminish in
latter-stage disease. Disease-stage effects have been noted in AD previ
ously where the expression of QUIN in post-mortem brain tissue is
reduced in later Braak stages of the disease (Guillemin et al., 2005). As
the immediate fate of 3-HAA along the major KP branch is conversion to
2-amino-3-carboxymuconate-6-semialdehyde (ACMS) by the enzyme 3hydroxyanthranilic-acid‑oxygenase (3-HAO), other mechanisms which
reduce 3-HAO function, could also be potential explanations of high 3HAA. This would also explain the significantly decreased levels of PIC
we observed.
Whatever the precise mechanism, there are many potential impacts
of increased 3-HAA on dementia processes. Mechanistically, 3-HAA is
regarded as redox active and/or redox regulatory with early data
describing a direct neurotoxic effect (Okuda et al., 1998) mediated by
metal ion reduction (Goldstein et al., 2000). Other studies point to
antioxidant effects (Krause et al., 2011; Oh et al., 2004) and, on balance,
it seems more likely that 3-HAA would act as a reactive oxygen species
(ROS) detoxifier rather than a toxic ROS generator. If indeed 3-HAA
does scavenge ROS, this would likely act to reduce both amyloid and
tau phenomena enhanced by the neuroinflammation-ROS axis. Despite
the potential links, no reports have yet emerged that describe how 3HAA modulations may impact formation of tau tangles.
Adaptive immunity, mediated by B- and T- cells, has attracted
increasing attention in AD and has been shown to enhance amyloid
clearance (Baruch et al., 2015). Studies in murine AD models featuring
Aβ pathology confirm brain CD3+ T-cell infiltration correlating with Aβ
plaque load (Ferretti et al., 2016). Studies also show increased levels of
CD3+ T-cells in AD patients relative to age-matched healthy controls
(Togo et al., 2002). In 3xTg AD mice, adoptive transfer of nonspecific
regulatory T cells (Tregs) reduced Aβ burden and improved cognitive
defects whereas depletion of Tregs worsened cognitive defects (Baek
et al., 2016). Since Munn et al., showed that activation of the KP resulted
in maternal-fetal tolerance mediated by the suppression of T-cells (Munn
et al., 1998), interest in the immunological aspects of KP metabolites has
grown. Relevant observations include that 3-HAA induced activated Tcell death by depleting intracellular glutathione but spared nonactivated T-cells (Lee et al., 2013). 3-HAA also reduced expression of
pro-inflammatory cytokines (interleukin (IL)-12, IL-6 and Tumour

Table 3
Logistic regression odds-ratio model results.
Metabolite

Non-progressor (N = 73) /
Progressor (N = 166)

TRP

1.05 (1, 1.09)*

KYN

0.792 (0.409, 1.54)

3-HK

1.02 (1.01, 1.03)**

3-HAA

1.19 (1.14, 1.25)****

AA

1.03 (0.998, 1.06)

PIC
QUIN

0.99 (0.986, 0.993)****
0.999 (0.999, 1)*

KYNA

1.05 (1.01, 1.09)*

K/ T

0.982 (0.96, 1.01)

3-HK/ KYN

1.04 (1.02, 1.07)**

3-HAA/ AA

35.3 (14, 104)****
0.0013 (2.92e-05, 0.0488)
***

PIC/ QUIN
QUIN/
KYNA

0.981 (0.972, 0.99)****

CN (N = 51/
101)

MCI (N = 22/ 65)

1.07 (1.01,
1.13)*
0.5 (0.211,
1.16)

1.01 (0.943,
1.08)
1.32 (0.407,
4.58)
1.02 (0.998,
1.04)
1.15 (1.09, 1.24)
****

1.02 (1, 1.04)*
1.25 (1.17,
1.36)****
1.02 (0.979,
1.06)
0.992 (0.988,
0.996)***
0.999 (0.998, 1)
1.05 (1, 1.1)
0.951 (0.916,
0.983)**
1.05 (1.02,
1.09)**
58.8 (16.1, 289)
****
0.00471 (4.87e05, 0.367)*
0.984 (0.973,
0.995)**

1.05 (0.99, 1.12)
0.982 (0.972,
0.99)****
0.999 (0.998, 1)
1.04 (0.965,
1.12)
1.02 (0.98, 1.06)
1.02 (0.988,
1.07)
18.7 (5.01, 96.9)
****
0.000161 (1.06e07, 0.128)*
0.974 (0.957,
0.99)**

Odds ratio (95% confidence interval) results on the ability of kynurenine me
tabolites to distinguish the difference between progressor and non-progressor
participants. These models take into account the effects of baseline age, sex
and apolipoprotein E (APOE) ε4 allele carrier/ non-carrier status. Logistic
regression models on each metabolite were applied independently to three
baseline groups; Progressors and non-progressors, cognitively normal (CN) and
mild cognitive impaired (MCI). Top row shows the number of non-progressor
and progressor individuals in parenthesis for each group, separated by a for
ward slash. TRP (Tryptophan), KYN (kynurenine), 3-HK (3-hydroxykynurenine),
3-HAA (3-hydroxyanthranilic acid), AA (anthranilic acid), PIC (picolinic acid),
QUIN (quinolinic acid), KYNA (kynurenic acid), and K/T (kynurenine/ trypto
phan ratio). Metabolite significance denoted by * p < 0.05, ** p < 0.01, *** p <
0.001 and **** p < 0.0001.

may reflect the fact that KP concentrations may not be the same at the
site of active disease. Indeed, we previously reported that only plasma
concentrations of KYN, 3-HK, AA and PIC correlated to CSF levels (Ja
cobs et al., 2019). Alternatively, it may be that KP metabolites only have
a weak secondary link to amyloid phenomena (as shown in Supple
mentary Table 3) with associations being stronger for neuro
inflammation and/or tau pathology. This could also explain, in part,
why Ervik found that KP metabolites only changed in non-APOE ε4 AD
(Ervik et al., 2019), whereas in APOE ε4 AD, amyloid aggregation is the
dominant pathological mechanism and may be largely independent of
the KP.
As noted above, the most striking finding in this study is that
increased plasma 3-HAA/AA ratio at baseline strongly predicted the risk
that CN or MCI participants will progress to either MCI or AD. This is a
novel finding and may represent a new prognostic tool to monitor risk of
cognitive decline. Previous single-point studies of the KP, conducted
after disease diagnosis, show that plasma concentrations of 3-HAA are
typically decreased, while AA is increased, leading to lower 3-HAA/AA
ratios. For example, significant decreases in plasma 3-HAA have been
reported in late-stage Huntington's disease (Stoy et al., 2005) and others
found a significant decrease (30%) in 3-HAA in the plasma of AD pa
tients (Giil et al., 2017). We also previously reported a 30% decrease in
plasma 3-HAA in symptomatic AD patients but found that 3-HAA was
significantly increased in CSF (Jacobs et al., 2019). These findings,
amongst others, prompted the suggestion that low 3HAA/AA ratios
represent a marker for inflammation and its progression (Darlington
et al., 2010) which may constitute a ‘cleaning-up’ mechanism. Hence, it
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Necrosis Factor (TNF-α) in bone marrow-derived dendritic cells
(BMDCs) stimulated with lipopolysaccharide (Lee et al., 2013).
Considering these observations, it is reasonable to speculate that, if
indeed adaptive immunity is important in clearing amyloid, then
increased 3-HAA is highly likely to interfere with this mechanism and
may thus be a biomarker of impaired adaptive immunological response
in pre-symptomatic dementia.
While strong results for the 3-HAA/AA ratio amongst others were
found, this study also has limitations. During the years since AIBL
conception, participants donated multiple longitudinal blood samples.
However, at the time of sample collection for this particular project, the
number of samples collected for progressor and non-progressors was
unbalanced and as such we used only baseline samples for KP analyses.
Future research will examine longitudinal samples from a larger selec
tion of AIBL participants, to ensure balanced numbers of both progressor
and non-progressor groups. A second limitation is the small sample size
of the PET amyloid imaging group, while no direct correlations with Aβ
load were observed, we cannot rule out that with increased samples our
results might be different.
The current study is the first to highlight the association of KP me
tabolites with a significant cognitive change prior to AD diagnosis.
Further work is needed to validate these findings in other populations
using both cross-sectional and longitudinal designs. Notwithstanding,
our current results have shown an intriguing, previously unreported
finding, strongly linking increased plasma 3-HAA levels in older adult
AIBL study participants to risk of progressing to MCI or AD. With further
validation this finding may also have translational potential as an
indicative biomarker, highlighting a possible therapeutic window for
either preventative strategies or treatment.

study. We would also like to acknowledge the whole AIBL team who
work tirelessly across multiple sites to provide the data for analyses.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.nbd.2022.105783.
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